<?xml version='1.0' encoding='utf-8'?>
<document id="22858177"><sentence text="Bioavailability and tolerability of combination treatment with revaprazan 200 mg + itopride 150 mg: a randomized crossover study in healthy male Korean volunteers."><entity charOffset="63-73" id="DDI-PubMed.22858177.s1.e0" text="revaprazan" /></sentence><sentence text="To date, no definitive treatment of functional dyspepsia (FD) has been proven to be effective and reasonably well-tolerated" /><sentence text=" Proton pump inhibitors (PPIs) combined with prokinetic agents are considered an effective option" /><sentence text=" Revaprazan is a selective potassium-competitive acid blocker that reversibly inhibits gastric H(+)/K(+)-ATPase and shows effective acid suppression comparable to PPIs"><entity charOffset="1-11" id="DDI-PubMed.22858177.s4.e0" text="Revaprazan" /><entity charOffset="27-36" id="DDI-PubMed.22858177.s4.e1" text="potassium" /><pair ddi="false" e1="DDI-PubMed.22858177.s4.e0" e2="DDI-PubMed.22858177.s4.e0" /><pair ddi="false" e1="DDI-PubMed.22858177.s4.e0" e2="DDI-PubMed.22858177.s4.e1" /></sentence><sentence text=" Itopride is a prokinetic agent that has anticholinesterase activity as well as dopamine D(2) receptor antagonistic activity"><entity charOffset="1-9" id="DDI-PubMed.22858177.s5.e0" text="Itopride" /><entity charOffset="80-88" id="DDI-PubMed.22858177.s5.e1" text="dopamine" /><pair ddi="false" e1="DDI-PubMed.22858177.s5.e0" e2="DDI-PubMed.22858177.s5.e0" /><pair ddi="false" e1="DDI-PubMed.22858177.s5.e0" e2="DDI-PubMed.22858177.s5.e1" /></sentence><sentence text=" For this reason, revaprazan and itopride have been prescribed for FD; however, no available studies have reported the pharmacokinetic interactions of these 2 drugs"><entity charOffset="18-28" id="DDI-PubMed.22858177.s6.e0" text="revaprazan" /><entity charOffset="33-41" id="DDI-PubMed.22858177.s6.e1" text="itopride" /><pair ddi="false" e1="DDI-PubMed.22858177.s6.e0" e2="DDI-PubMed.22858177.s6.e0" /><pair ddi="false" e1="DDI-PubMed.22858177.s6.e0" e2="DDI-PubMed.22858177.s6.e1" /></sentence><sentence text="" /><sentence text="The objective of this study was to compare the bioavailability and tolerability of revaprazan and itopride combination therapy to those of equally dosed monotherapies to acquire basic drug-drug interaction information about revaprazan"><entity charOffset="83-93" id="DDI-PubMed.22858177.s8.e0" text="revaprazan" /><entity charOffset="98-106" id="DDI-PubMed.22858177.s8.e1" text="itopride" /><entity charOffset="224-234" id="DDI-PubMed.22858177.s8.e2" text="revaprazan" /><pair ddi="false" e1="DDI-PubMed.22858177.s8.e0" e2="DDI-PubMed.22858177.s8.e0" /><pair ddi="false" e1="DDI-PubMed.22858177.s8.e0" e2="DDI-PubMed.22858177.s8.e1" /><pair ddi="false" e1="DDI-PubMed.22858177.s8.e0" e2="DDI-PubMed.22858177.s8.e2" /><pair ddi="false" e1="DDI-PubMed.22858177.s8.e1" e2="DDI-PubMed.22858177.s8.e1" /><pair ddi="false" e1="DDI-PubMed.22858177.s8.e1" e2="DDI-PubMed.22858177.s8.e2" /></sentence><sentence text="" /><sentence text="This multiple-dose, randomized crossover study was conducted in healthy male Korean subjects" /><sentence text=" Subjects received, in randomized sequence, a 7-day oral dose of revaprazan 200 mg once daily, itopride 50 mg TID, or both"><entity charOffset="65-75" id="DDI-PubMed.22858177.s11.e0" text="revaprazan" /><entity charOffset="95-103" id="DDI-PubMed.22858177.s11.e1" text="itopride" /><pair ddi="false" e1="DDI-PubMed.22858177.s11.e0" e2="DDI-PubMed.22858177.s11.e0" /><pair ddi="false" e1="DDI-PubMed.22858177.s11.e0" e2="DDI-PubMed.22858177.s11.e1" /></sentence><sentence text=" Each treatment period was separated by a 7-day washout period" /><sentence text=" Blood samples were collected for up to 24 hours following the last dose at steady state, and drug concentrations were determined using validated LC/MS-MS" /><sentence text=" Pharmacokinetic properties were obtained using noncompartmental analysis" /><sentence text=" Drug tolerability was assessed throughout the study, using measurements of vital signs, clinical chemistry testing, and interviews" /><sentence text="" /><sentence text="A total of 30 subjects were enrolled in the study" /><sentence text=" Among them, 28 subjects completed revaprazan treatment, and 27 completed the study (3 subjects were withdrawn)"><entity charOffset="35-45" id="DDI-PubMed.22858177.s18.e0" text="revaprazan" /></sentence><sentence text=" The geometric mean ratios (GMRs) (90% CI) of C(max,ss), and AUC(τ,ss) with revaprazan were 0" /><sentence text="92 (0" /><sentence text="84-1" /><sentence text="00) and 0" /><sentence text="96 (0" /><sentence text="89-1" /><sentence text="03), respectively" /><sentence text=" The GMRs of C(max,ss) and AUC(τ,ss) with itopride were 1"><entity charOffset="42-50" id="DDI-PubMed.22858177.s26.e0" text="itopride" /></sentence><sentence text="07 (0" /><sentence text="96-1" /><sentence text="20) and 1" /><sentence text="12 (1" /><sentence text="06-1" /><sentence text="18), respectively" /><sentence text=" A total of 15 adverse events (AEs) were reported in 8 subjects" /><sentence text=" All AEs were considered to be mild, and there were no clinically significant differences between treatment groups" /><sentence text="" /><sentence text="The findings from this study suggest bioequivalence between revaprazan given as monotherapy and in combination with itopride in these healthy Korean male volunteers, with no clinical significant drug-drug interaction"><entity charOffset="116-124" id="DDI-PubMed.22858177.s36.e0" text="itopride" /></sentence><sentence text=" All treatments in this study was generally well tolerated" /><sentence text=" ClinicalTrials" /><sentence text="gov identifier: NCT0133289" /><sentence text="" /></document>